Improving the efficiency of the development of drugs for stroke

The mortality and morbidity associated with stroke makes the development of new drugs a research priority. Recent unsuccessful clinical trials have reduced enthusiasm for the development of neuroprotective drugs. Here, we use empirical evidence derived from systematic reviews of stroke drug developm...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Stroke 2012-07, Vol.7 (5), p.371-377
Main Authors: Howells, David W., Sena, Emily S., O'Collins, Victoria, Macleod, Malcolm R.
Format: Article
Language:English
Subjects:
Animal Experimentation
Clinical trials
Costs and Cost Analysis
Drug development
Drug Discovery - economics
Drug Evaluation, Preclinical - economics
Economics
Humans
Morbidity
Mortality
Neuroprotection
Neuroprotective Agents - therapeutic use
pharmacoecomonics
Stroke
Stroke - drug therapy
Stroke - economics
Technology, Pharmaceutical - economics
translation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The mortality and morbidity associated with stroke makes the development of new drugs a research priority. Recent unsuccessful clinical trials have reduced enthusiasm for the development of neuroprotective drugs. Here, we use empirical evidence derived from systematic reviews of stroke drug development to identify stages of drug development which might be improved. We then propose exemplar strategies which may be helpful, along with some basic economic modelling of what the impact of such strategies might be. This suggests that relatively straightforward measures might reduce the costs of drug development by $5.8 bn or 31%.
ISSN:1747-4930
1747-4949
DOI:10.1111/j.1747-4949.2012.00805.x